Intensified Inflammatory Reaction of Actinic Keratoses after Single Application of Topical 5-Fluorouracil in a Patient Treated with Nilotinib for Chronic Myeloid Leukemia
Actinic keratoses frequently occur in sun-exposed areas of the skin and, today, a variety of therapeutic options are available, including topical application of 5-fluorouracil (5-FU). Usually, 5-FU ointment needs to be applied twice daily for 2–4 weeks to achieve a therapeutic skin reaction. Here, w...
Gespeichert in:
| Veröffentlicht in: | Dermatology (Basel) 2009-01, Vol.219 (4), p.341-343 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 343 |
|---|---|
| container_issue | 4 |
| container_start_page | 341 |
| container_title | Dermatology (Basel) |
| container_volume | 219 |
| creator | Schmid-Wendtner, Monika-Hildegard Wendtner, Clemens M. |
| description | Actinic keratoses frequently occur in sun-exposed areas of the skin and, today, a variety of therapeutic options are available, including topical application of 5-fluorouracil (5-FU). Usually, 5-FU ointment needs to be applied twice daily for 2–4 weeks to achieve a therapeutic skin reaction. Here, we report on an immediate inflammatory reaction after single application of topical 5-FU in a patient receiving systemic treatment with the multitargeted tyrosine kinase inhibitor nilotinib for chronic myeloid leukemia. This side effect of nilotinib is new and might be of clinical relevance. We, therefore, discuss possible modes of action including other reports about different tyrosine kinase inhibitors which led to regression of aggravation of actinic keratoses. |
| doi_str_mv | 10.1159/000221006 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pasca</sourceid><recordid>TN_cdi_pascalfrancis_primary_22162344</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1917950131</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-b2b13ff460a29524aa518274987130c082b8593419af1a0c787669020e30f02b3</originalsourceid><addsrcrecordid>eNpd0U1v1DAQBuAIgWgpHLgjZCGBxCHgjyRrH1crWlYsH4LlHE2849atY6d2omr_Er8SR7sUxMlj-dG8tqconjP6jrFavaeUcs4obR4Up6zirFRS8Ie5pkyWsmnqk-JJStczkwv1uDhhqmokp-y0-LX2I_pkjcUdWXvjoO9hDHFPviPo0QZPgiHLXHmrySeM-TBhImBGjOSH9ZcOyXIYnNXwR2_DkHeO1OW5m0IMUwRtHbGeAPmWFfqRbCPCmCPv7HhFvlgX5oCOmBDJ6iqGOezzHl2wO7LB6QZ7C0-LRwZcwmfH9az4ef5hu_pYbr5erFfLTamFEmPZ8Y4JY6qGAlc1rwBqJvmiUnLBBNVU8k7WSlRMgWFA9UIumkZRTlFQQ3knzoo3h75DDLcTprHtbdLoHHgMU2p5blMzTjN89R-8zm_1-W7tnCcaKWf09oB0DClFNO0QbQ9x3zLaztNr76eX7ctjw6nrcfdXHseVwesjgJR_2ETw2qZ7l9s0XFRVdi8O7gbiJcZ_wZzzG80pqms</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>274936880</pqid></control><display><type>article</type><title>Intensified Inflammatory Reaction of Actinic Keratoses after Single Application of Topical 5-Fluorouracil in a Patient Treated with Nilotinib for Chronic Myeloid Leukemia</title><source>MEDLINE</source><source>Karger Journals</source><source>Alma/SFX Local Collection</source><creator>Schmid-Wendtner, Monika-Hildegard ; Wendtner, Clemens M.</creator><creatorcontrib>Schmid-Wendtner, Monika-Hildegard ; Wendtner, Clemens M.</creatorcontrib><description>Actinic keratoses frequently occur in sun-exposed areas of the skin and, today, a variety of therapeutic options are available, including topical application of 5-fluorouracil (5-FU). Usually, 5-FU ointment needs to be applied twice daily for 2–4 weeks to achieve a therapeutic skin reaction. Here, we report on an immediate inflammatory reaction after single application of topical 5-FU in a patient receiving systemic treatment with the multitargeted tyrosine kinase inhibitor nilotinib for chronic myeloid leukemia. This side effect of nilotinib is new and might be of clinical relevance. We, therefore, discuss possible modes of action including other reports about different tyrosine kinase inhibitors which led to regression of aggravation of actinic keratoses.</description><identifier>ISSN: 1018-8665</identifier><identifier>EISSN: 1421-9832</identifier><identifier>DOI: 10.1159/000221006</identifier><identifier>PMID: 19468201</identifier><language>eng</language><publisher>Basel, Switzerland: Karger</publisher><subject>Administration, Cutaneous ; Aged ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - adverse effects ; Biological and medical sciences ; Clinical outcomes ; Dermatitis ; Dermatologic Agents - administration & dosage ; Dermatologic Agents - therapeutic use ; Dermatology ; Drug therapy ; Drug Therapy, Combination ; Fluorouracil - administration & dosage ; Fluorouracil - therapeutic use ; Forehead - pathology ; Hematologic and hematopoietic diseases ; Humans ; Keratosis, Actinic - complications ; Keratosis, Actinic - drug therapy ; Keratosis, Actinic - pathology ; Leukemia ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Male ; Medical sciences ; Medical treatment ; News and Views ; Pyrimidines - administration & dosage ; Pyrimidines - adverse effects ; Scalp - pathology ; Side effects ; Skin diseases ; Time Factors ; Treatment Outcome</subject><ispartof>Dermatology (Basel), 2009-01, Vol.219 (4), p.341-343</ispartof><rights>2009 S. Karger AG, Basel</rights><rights>2015 INIST-CNRS</rights><rights>Copyright 2009 S. Karger AG, Basel.</rights><rights>Copyright (c) 2009 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-b2b13ff460a29524aa518274987130c082b8593419af1a0c787669020e30f02b3</citedby><cites>FETCH-LOGICAL-c393t-b2b13ff460a29524aa518274987130c082b8593419af1a0c787669020e30f02b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2427,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22162344$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19468201$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schmid-Wendtner, Monika-Hildegard</creatorcontrib><creatorcontrib>Wendtner, Clemens M.</creatorcontrib><title>Intensified Inflammatory Reaction of Actinic Keratoses after Single Application of Topical 5-Fluorouracil in a Patient Treated with Nilotinib for Chronic Myeloid Leukemia</title><title>Dermatology (Basel)</title><addtitle>Dermatology</addtitle><description>Actinic keratoses frequently occur in sun-exposed areas of the skin and, today, a variety of therapeutic options are available, including topical application of 5-fluorouracil (5-FU). Usually, 5-FU ointment needs to be applied twice daily for 2–4 weeks to achieve a therapeutic skin reaction. Here, we report on an immediate inflammatory reaction after single application of topical 5-FU in a patient receiving systemic treatment with the multitargeted tyrosine kinase inhibitor nilotinib for chronic myeloid leukemia. This side effect of nilotinib is new and might be of clinical relevance. We, therefore, discuss possible modes of action including other reports about different tyrosine kinase inhibitors which led to regression of aggravation of actinic keratoses.</description><subject>Administration, Cutaneous</subject><subject>Aged</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Clinical outcomes</subject><subject>Dermatitis</subject><subject>Dermatologic Agents - administration & dosage</subject><subject>Dermatologic Agents - therapeutic use</subject><subject>Dermatology</subject><subject>Drug therapy</subject><subject>Drug Therapy, Combination</subject><subject>Fluorouracil - administration & dosage</subject><subject>Fluorouracil - therapeutic use</subject><subject>Forehead - pathology</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Keratosis, Actinic - complications</subject><subject>Keratosis, Actinic - drug therapy</subject><subject>Keratosis, Actinic - pathology</subject><subject>Leukemia</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medical treatment</subject><subject>News and Views</subject><subject>Pyrimidines - administration & dosage</subject><subject>Pyrimidines - adverse effects</subject><subject>Scalp - pathology</subject><subject>Side effects</subject><subject>Skin diseases</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>1018-8665</issn><issn>1421-9832</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpd0U1v1DAQBuAIgWgpHLgjZCGBxCHgjyRrH1crWlYsH4LlHE2849atY6d2omr_Er8SR7sUxMlj-dG8tqconjP6jrFavaeUcs4obR4Up6zirFRS8Ie5pkyWsmnqk-JJStczkwv1uDhhqmokp-y0-LX2I_pkjcUdWXvjoO9hDHFPviPo0QZPgiHLXHmrySeM-TBhImBGjOSH9ZcOyXIYnNXwR2_DkHeO1OW5m0IMUwRtHbGeAPmWFfqRbCPCmCPv7HhFvlgX5oCOmBDJ6iqGOezzHl2wO7LB6QZ7C0-LRwZcwmfH9az4ef5hu_pYbr5erFfLTamFEmPZ8Y4JY6qGAlc1rwBqJvmiUnLBBNVU8k7WSlRMgWFA9UIumkZRTlFQQ3knzoo3h75DDLcTprHtbdLoHHgMU2p5blMzTjN89R-8zm_1-W7tnCcaKWf09oB0DClFNO0QbQ9x3zLaztNr76eX7ctjw6nrcfdXHseVwesjgJR_2ETw2qZ7l9s0XFRVdi8O7gbiJcZ_wZzzG80pqms</recordid><startdate>20090101</startdate><enddate>20090101</enddate><creator>Schmid-Wendtner, Monika-Hildegard</creator><creator>Wendtner, Clemens M.</creator><general>Karger</general><general>S. Karger AG</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>20090101</creationdate><title>Intensified Inflammatory Reaction of Actinic Keratoses after Single Application of Topical 5-Fluorouracil in a Patient Treated with Nilotinib for Chronic Myeloid Leukemia</title><author>Schmid-Wendtner, Monika-Hildegard ; Wendtner, Clemens M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-b2b13ff460a29524aa518274987130c082b8593419af1a0c787669020e30f02b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Administration, Cutaneous</topic><topic>Aged</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Clinical outcomes</topic><topic>Dermatitis</topic><topic>Dermatologic Agents - administration & dosage</topic><topic>Dermatologic Agents - therapeutic use</topic><topic>Dermatology</topic><topic>Drug therapy</topic><topic>Drug Therapy, Combination</topic><topic>Fluorouracil - administration & dosage</topic><topic>Fluorouracil - therapeutic use</topic><topic>Forehead - pathology</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Keratosis, Actinic - complications</topic><topic>Keratosis, Actinic - drug therapy</topic><topic>Keratosis, Actinic - pathology</topic><topic>Leukemia</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medical treatment</topic><topic>News and Views</topic><topic>Pyrimidines - administration & dosage</topic><topic>Pyrimidines - adverse effects</topic><topic>Scalp - pathology</topic><topic>Side effects</topic><topic>Skin diseases</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schmid-Wendtner, Monika-Hildegard</creatorcontrib><creatorcontrib>Wendtner, Clemens M.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Toxicology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Dermatology (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schmid-Wendtner, Monika-Hildegard</au><au>Wendtner, Clemens M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intensified Inflammatory Reaction of Actinic Keratoses after Single Application of Topical 5-Fluorouracil in a Patient Treated with Nilotinib for Chronic Myeloid Leukemia</atitle><jtitle>Dermatology (Basel)</jtitle><addtitle>Dermatology</addtitle><date>2009-01-01</date><risdate>2009</risdate><volume>219</volume><issue>4</issue><spage>341</spage><epage>343</epage><pages>341-343</pages><issn>1018-8665</issn><eissn>1421-9832</eissn><abstract>Actinic keratoses frequently occur in sun-exposed areas of the skin and, today, a variety of therapeutic options are available, including topical application of 5-fluorouracil (5-FU). Usually, 5-FU ointment needs to be applied twice daily for 2–4 weeks to achieve a therapeutic skin reaction. Here, we report on an immediate inflammatory reaction after single application of topical 5-FU in a patient receiving systemic treatment with the multitargeted tyrosine kinase inhibitor nilotinib for chronic myeloid leukemia. This side effect of nilotinib is new and might be of clinical relevance. We, therefore, discuss possible modes of action including other reports about different tyrosine kinase inhibitors which led to regression of aggravation of actinic keratoses.</abstract><cop>Basel, Switzerland</cop><pub>Karger</pub><pmid>19468201</pmid><doi>10.1159/000221006</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1018-8665 |
| ispartof | Dermatology (Basel), 2009-01, Vol.219 (4), p.341-343 |
| issn | 1018-8665 1421-9832 |
| language | eng |
| recordid | cdi_pascalfrancis_primary_22162344 |
| source | MEDLINE; Karger Journals; Alma/SFX Local Collection |
| subjects | Administration, Cutaneous Aged Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Biological and medical sciences Clinical outcomes Dermatitis Dermatologic Agents - administration & dosage Dermatologic Agents - therapeutic use Dermatology Drug therapy Drug Therapy, Combination Fluorouracil - administration & dosage Fluorouracil - therapeutic use Forehead - pathology Hematologic and hematopoietic diseases Humans Keratosis, Actinic - complications Keratosis, Actinic - drug therapy Keratosis, Actinic - pathology Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Medical treatment News and Views Pyrimidines - administration & dosage Pyrimidines - adverse effects Scalp - pathology Side effects Skin diseases Time Factors Treatment Outcome |
| title | Intensified Inflammatory Reaction of Actinic Keratoses after Single Application of Topical 5-Fluorouracil in a Patient Treated with Nilotinib for Chronic Myeloid Leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T07%3A18%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intensified%20Inflammatory%20Reaction%20of%20Actinic%20Keratoses%20after%20Single%20Application%20of%20Topical%205-Fluorouracil%20in%20a%20Patient%20Treated%20with%20Nilotinib%20for%20Chronic%20Myeloid%20Leukemia&rft.jtitle=Dermatology%20(Basel)&rft.au=Schmid-Wendtner,%20Monika-Hildegard&rft.date=2009-01-01&rft.volume=219&rft.issue=4&rft.spage=341&rft.epage=343&rft.pages=341-343&rft.issn=1018-8665&rft.eissn=1421-9832&rft_id=info:doi/10.1159/000221006&rft_dat=%3Cproquest_pasca%3E1917950131%3C/proquest_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=274936880&rft_id=info:pmid/19468201&rfr_iscdi=true |